Wuhan Healthgen Biotechnology Corp. (SHA:688765)

Market Cap	25.60B
Revenue (ttm)	28.39M
Net Income (ttm)	-154.40M
Shares Out	357.50M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,386,837
Average Volume	2,822,304
Open	69.41
Previous Close	69.41
Day's Range	68.68 - 72.33
52-Week Range	68.68 - 132.03
Beta	n/a
RSI	39.36
Earnings Date	n/a

About SHA:688765

Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial growth factor, recombinant human keratinocyte growth factor, recombinant human...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 158
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688765

Financial Performance

In 2024, SHA:688765's revenue was 25.22 million, an increase of 3.92% compared to the previous year's 24.26 million. Losses were -151.37 million, -19.04% less than in 2023.